Therapeutic potential of nanocarrier for overcoming to P-glycoprotein

References

• Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. Int J Pharm Invest 2012;2:2–11
   PubMedGoogle Scholar
• Yamaguchi H, Yano I, Saito H, Inui K-I. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 2002;300:1063–9
   PubMed Web of Science ®Google Scholar
• Frezard F, Pereira-Maia E, Quidu P, et al. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur J Biochem 2001;268:1561–7
   PubMedGoogle Scholar
• Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347–59
   PubMed Web of Science ®Google Scholar
• Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991–2002
   PubMed Web of Science ®Google Scholar
• Huang I-P, Sun S-P, Cheng S-H, et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011;10:761–9
   PubMed Web of Science ®Google Scholar
• Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10:73–9
   PubMed Web of Science ®Google Scholar
• Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003;11:391–406
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152–62
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. Annu Rev Pharmacol Toxicol 1999;39:361–98
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011;50:161–78
   PubMed Web of Science ®Google Scholar
• Edwards JE, Alcorn J, Savolainen J, et al. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier. Antimicrob Agents Chemother 2005;49:1626–8
   PubMed Web of Science ®Google Scholar
• Melaine N, Liénard M-O, Dorval I, et al. Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol Reprod 2002;67:1699–707
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Smith MM, Müller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481–91
   PubMed Web of Science ®Google Scholar
• Goren D, Horowitz AT, Tzemach D, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6:1949–57
   PubMed Web of Science ®Google Scholar
• Beaulieu E, Demeule M, Ghitescu L, Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997;326:539–44
   PubMed Web of Science ®Google Scholar
• Sharom FJ, Liu R, Qu Q, Romsicki Y. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol 2001;12:257–65
   PubMed Web of Science ®Google Scholar
• Srivalli KMR, Lakshmi P. Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharm Sci 2012;48:353–67
   Web of Science ®Google Scholar
• Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12:46–78
   PubMed Web of Science ®Google Scholar
• Bansal T, Akhtar N, Jaggi M, et al. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009;14:1067–74
   PubMed Web of Science ®Google Scholar
• Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010;5:597–615
   PubMed Web of Science ®Google Scholar
• Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003;46:4805–17
   PubMed Web of Science ®Google Scholar
• Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterationsin membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995;228:1020–9
   PubMedGoogle Scholar
• Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 2007;13:3276–85
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and the dance macabre between humans and bacteria. Nat Rev Drug Discov 2007;6:56–65
   PubMed Web of Science ®Google Scholar
• Kerr D, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239–42
   PubMed Web of Science ®Google Scholar
• Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001;92:1577–90
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861–79
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv 2014. [Epub ahead of print]. doi:10.3109/10717544.2013.879355
   Google Scholar
• Lo Y-L. Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 2003;90:37–48
   PubMed Web of Science ®Google Scholar
• Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005;25:445–53
   PubMed Web of Science ®Google Scholar
• Liu C, Wu J, Shi B, et al. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm 2006;32:115–23
   PubMed Web of Science ®Google Scholar
• Carreno-Gomez B, Duncan R. Compositions with enhanced oral bioavailability. Google Patents, 2001
   Google Scholar
• Carreno-Gomez B, Duncan R. Compositions with enhanced oral bioavailability. US Patent 20,030,211,072, 2003
   Google Scholar
• Föger F, Kafedjiiski K, Hoyer H, et al. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J Drug Target 2007;15:132–9
   PubMed Web of Science ®Google Scholar
• Shen Q, Lin Y, Handa T, et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006;313:49–56
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002;4:193–205
   Google Scholar
• Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci 2007;10:319–31
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119–31
   PubMed Web of Science ®Google Scholar
• Mahmoudzadeh M, Fassihi A, Emami J, et al. Physicochemical, pharmaceutical and biological approaches toward designing optimized and efficient hydrophobically modified chitosan-based polymeric micelles as a nanocarrier system for targeted delivery of anticancer drugs. J Drug Target 2013;21:693–709
   PubMed Web of Science ®Google Scholar
• Moutinho CG, Matos CM, Teixeira JA, Balcao VM. Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art. J Drug Target 2012;20:114–41
   PubMed Web of Science ®Google Scholar
• Niu J, Huang A, Xiao Y, et al. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier. J Drug Target 2013;21:415–26
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–92
   PubMed Web of Science ®Google Scholar
• Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009;37:300–5
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng X-L, Fang D-L, et al. Dual Agent Loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model. Int J Mol Sci 2014;15:2761–72
   PubMed Web of Science ®Google Scholar
• Emilienne Soma C, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000;21:1–7
   PubMed Web of Science ®Google Scholar
• Chavanpatil MD, Khdair A, Gerard B, et al. Surfactant–polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 2007;4:730–8
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P, Minko T, Lu Z-R. HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000;50:61–81
   PubMed Web of Science ®Google Scholar
• Nori A, Kopeček J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005;57:609–36
   PubMed Web of Science ®Google Scholar
• Omelyanenko V, Kopečková P, Gentry C, Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 1998;53:25–37
   PubMed Web of Science ®Google Scholar
• Schmitz T, Hombach J, Bernkop-Schnürch A. Chitosan-N-acetyl cysteine conjugates: in vitro evaluation of permeation enhancing and P-glycoprotein inhibiting properties. Drug Deliv 2008;15:245–52
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed 2009;48:5418–29
   PubMed Web of Science ®Google Scholar
• Jones M-C, Leroux J-C. Polymeric micelles – a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48:101–11
   PubMed Web of Science ®Google Scholar
• Mourya V, Inamdar N, Nawale R, Kulthe S. Polymeric micelles: general considerations and their applications. Indian J Pharm Educ Res 2011;45:128–38
   Web of Science ®Google Scholar
• Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv 2013;2013:Article ID 340315, 15 pages
   Google Scholar
• Yao H-J, Ju R-J, Wang X-X, et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011;32:3285–302
   PubMed Web of Science ®Google Scholar
• Wei Z, Yuan S, Hao J, Fang X. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. Eur J Pharm Biopharm 2013;83:266–74
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee SH, Gan CW, Feng S-S. In vitro and in vivo investigation on PLA–TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 2008;25:1925–35
   PubMed Web of Science ®Google Scholar
• Cambon A, Rey-Rico A, Barbosa S, et al. Poly (styrene oxide)-poly (ethylene oxide) block copolymers: from “classical” chemotherapeutic nanocarriers to active cell-response inducers. J Control Release 2013;167:68–75
   PubMed Web of Science ®Google Scholar
• Duan X, Xiao J, Yin Q, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013;7:5858–69
   PubMed Web of Science ®Google Scholar
• Alagusundaram M, Umashankari K, Badarinath AV, et al. Microspheres as a novel drug delivery sysytem – a review. Int J ChemTech Res 2009;1:526–34
   Google Scholar
• Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 2012;29:1–63
   PubMed Web of Science ®Google Scholar
• Derakhshandeh K, Hosseinalizadeh A, Nikmohammadi M. The effects of PLGA microparticles on intestinal absorption of p-glycoprotein substrate using the everted rat intestinal sac model. Arch Pharmacol Res 2011;34:1989–97
   PubMed Web of Science ®Google Scholar
• Liu Z, Bendayan R, Wu XY. Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance. J Pharm Pharmacol 2001;53:779–87
   PubMed Web of Science ®Google Scholar
• Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst 2013;30:369–409
   PubMed Web of Science ®Google Scholar
• Št’astný M, Plocová D, Etrych T, et al. HPMA-hydrogels containing cytostatic drugs: kinetics of the drug release and in vivo efficacy. J Control Release 2002;81:101–11
   PubMed Web of Science ®Google Scholar
• Št’astný M, Strohalm J, Plocova D, et al. A Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur J Cancer 1999;35:459–66
   PubMed Web of Science ®Google Scholar
• Garg T, Goyal AK. Biomaterial-based scaffolds – current status and future directions. Expert Opin Drug Deliv 2014;11:767–89
   PubMed Web of Science ®Google Scholar
• Mooberry LK, Nair M, Paranjape S, et al. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 2010;18:53–8
   PubMed Web of Science ®Google Scholar
• Bromberg L, Alakhov V. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 2003;88:11–22
   PubMed Web of Science ®Google Scholar
• Patelx H, Patel P. Dendrimer applications – a review. Int J Pharm BioSci 2013;4:454–63
   Google Scholar
• Sukumar UK, Bhushan B, Dubey P, et al. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. Int Nano Lett 2013;3:1–17
   Google Scholar
• D’Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004;95:447–53
   PubMed Web of Science ®Google Scholar
• Daming C, Qiwu X, Shixin G, et al. PAMAM-drug complex for delivering anticancer drug across blood-brain barrier in-vitro and in-vivo. Afr J Pharm Pharmacol 2009;3:227–33
   Web of Science ®Google Scholar
• Najlah M, Freeman S, Attwood D, D’Emanuele A. Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates. Bioconjug Chem 2007;18:937–46
   PubMed Web of Science ®Google Scholar
• Teow HM. An investigation of the use of dendrimer-based carrier to cross cellular barriers. Preston, Lancashire, England: University of Central Lancashire; 2010
   Google Scholar
• Zhou Y, Ning Q, Yu DN, et al. Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system. J Pharm Pharmacol 2014;66:903–11
   Google Scholar
• Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011;8:683–700
   PubMed Web of Science ®Google Scholar
• Barthelemy P, Laforet J, Farah N, Joachim J. Compritol® 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm 1999;47:87–90
   PubMed Web of Science ®Google Scholar
• Baviskar D, Amritkar A, Chaudhari H, Jain D. Modulation of drug release from nanocarriers loaded with a poorly water soluble drug (flurbiprofen) comprising natural waxes. Die Pharmazie – Int J Pharm Sci 2012;67:701–5
   Google Scholar
• Muèller RH, Maèder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Dharmala K, Yoo JW, Lee CH. Development of Chitosan–SLN Microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J Control Release 2008;131:190–7
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004;93:1993–2008
   PubMed Web of Science ®Google Scholar
• Yin Y-M, Cui F-D, Mu C-F, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009;140:86–94
   PubMed Web of Science ®Google Scholar
• Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci 2013;102:1343–54
   PubMed Web of Science ®Google Scholar
• Nornoo AO, Zheng H, Lopes LB, et al. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009;71:310–17
   PubMed Web of Science ®Google Scholar
• Hadinoto K, Sundaresan A, Cheow WS. Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 2013;85:427–43
   PubMed Web of Science ®Google Scholar
• de Verdiere AC, Dubernet C, Nemati F, et al. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 1994;33:504–8
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006;317:1372–81
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Benoit J-P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release 2006;112:208–13
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116:275–84
   PubMed Web of Science ®Google Scholar
• Shuhendler AJ, Cheung RY, Manias J, et al. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2010;119:255–69
   PubMed Web of Science ®Google Scholar
• Wan C, Letchford K, Jackson JK, Burt HM. The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance. Int J Nanomed 2012;8:379–91
   Web of Science ®Google Scholar
• Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 2009;9:399
   PubMed Web of Science ®Google Scholar
• Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010;148:241–8
   PubMed Web of Science ®Google Scholar
• Xu L, Li H, Wang Y, et al. Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors. Oncol Lett 2014;7:387–92
   PubMed Web of Science ®Google Scholar
• Lu H-L, Syu W-J, Nishiyama N, et al. Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo. J Control Release 2011;155:458–64
   PubMed Web of Science ®Google Scholar
• Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136:21–9
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010;31:358–65
   PubMed Web of Science ®Google Scholar
• Meng H, Liong M, Xia T, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539–50
   PubMed Web of Science ®Google Scholar
• Minko T, Kopečková P, Pozharov V, Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 1998;54:223–33
   PubMed Web of Science ®Google Scholar